Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $170M
Founded date: 2017
Investors 4
| Date | Name | Website |
| 09.05.2022 | E&Inve... | eninvestme... |
| 17.08.2023 | Hercules C... | htgc.com |
| 17.02.2022 | RA Capital... | racap.com |
| - | Adjuvant C... | adjuvantca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.03.2025 | Series B | $110M | - |
| 11.02.2022 | Series A | $60M | - |
Mentions in press and media 12
| Date | Title | Description |
| 24.07.2026 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 30 June 2026 with key figures for the first three months of the 2026/2027 financial year | Widespread strong performance In the first quarter of the 2026/2027 financial year, HBM Healthcare Investments generated a profit of CHF 238 million. Once again, net assets exceeded the CHF 2 billion mark as at 30 June 2026. The net asset ... |
| 18.03.2025 | Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in Immunization | In the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa... |
| 18.03.2025 | Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein Shingles | Curevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm... |
| 17.03.2025 | Curevo rounds up $110M to challenge GSK’s Shringrix, nabs Moncef Slaoui to lead board | In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former GSK leaders to its board. The biotech’s series B was led by new investor Medicxi, a European biotech VC with vaccine... |
| 17.03.2025 | Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine | - |
| 17.03.2025 | Curevo Raises $110M in Series B Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding. The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca... |
| 17.03.2025 | Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine | -- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business... |
| 11.02.2022 | Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot | Curevo CEO George Simeon. (Curevo Photo) Curevo has raised $60 million to develop a new vaccine for shingles, an often-painful condition caused by reactivation of the chickenpox virus. The new funding will enable the Seattle-based startup t... |
| 11.02.2022 | Green Cross : Curevo Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines | Curevo's lead program is CRV-101, an adjuvanted subunit vaccine for shingles, which has demonstrated robust immunogenicity and tolerability in Phase 1 trials Financing funds the 678-patient Phase 2b head-to-head trial of CRV-101 against Shi... |
| 11.02.2022 | Curevo Vaccine Raises $60M in Series A Funding | Curevo, a Seattle, WA-based clinical-stage biotechnology company, raised $60M in Series A funding. The round was led by RA Capital Management joined by Adjuvant Capital, Janus Henderson Investors, EN Investment, and founding investor GC Pha... |
Show more